Antisense modulation of beta-site APP-cleaving enzyme expression
AssigneeIsis Pharmaceuticals, Inc.
InventorKenneth W. Dobie
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of beta-site APP-cleaving enzyme. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding beta-site APP-cleaving enzyme. Methods of using these compounds for modulation of beta-site APP-cleaving enzyme expression and for treatment of diseases associated with expression of beta-site APP-cleaving enzyme are provided.
Claims20
A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding beta-site APP-cleaving enzyme, wherein said compound specifically hybridizes with said nucleic acid molecule encoding beta-site APP-cleaving enzyme and inhibits the expression of beta-site APP-cleaving enzyme.
A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of a preferred target region on a nucleic acid molecule encoding beta-site APP-cleaving enzyme.
Dependencies are inferred from the claim text.